sciclone pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals

SCLN 11.15

0.0%

Oct 20 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Captain Jack who wrote (1045)	7/16/2002 1:06:00 PM
From: Skywatcher	Read Replies (2) of 1137

ZADAXIN PRODUCES SUSTAINED RESPONSES IN MOST DIFFICULT TO TREAT HEPATITIS B PATIENTS San Mateo, CA, July 16, 2002 - SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced the results of a new study demonstrating that ZADAXIN® (thymalfasin, thymosin alpha 1) helps clear the hepatitis B virus in the most difficult to treat patients, those in the immune tolerant phase of this viral infection. Until this ZADAXIN clinical trial, virtually no treatment has been able to effectively cure hepatitis B in patients in the immune-tolerant phase of the viral infection. At the end of the 26 weeks of therapy and 52 weeks of follow-up observation, 15.6% of 32 hepatitis B immune-tolerant patients demonstrated a complete response to ZADAXIN therapy in combination with the nucleoside analogue famciclovir. By comparison, there were no responders among the 32 patients in each group that received either famciclovir monotherapy or placebo. OK....one more round from $2...... CC

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next